Hypoxia-induced gene expression in human macrophages: Implications for ischemic tissues and hypoxia-regulated gene therapy

American Journal of Pathology

Volumn 163, Issue 4, 2003, Pages 1233-1243

  Burke, Bernard ^a   Giannoudis, Athina ^a   Corke, Kevin P ^a   Gill, Dalvir ^a   Wells, Michael ^a   Ziegler Heitbrock, Loems ^b   Lewis, Claire E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; DNA BINDING PROTEIN INHIBITOR; GENE PRODUCT; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF DIFFERENTIATION 2; MATRILYSIN; MESSENGER RNA; NEUROMEDIN B RECEPTOR; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST TUMOR; CELL INFILTRATION; CELL TYPE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA MICROARRAY; GENE CONTROL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INDUCTION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; MACROPHAGE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 0141425768     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63483-9     Document Type: Article

References (64)

1. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic environment of human tumors: a review. Cancer Res 1989, 49:6449-6465
2. Kivisaari J: Oxygen and carbon dioxide tensions in healing tissue. Acta Chir Scand 1975, 141:693-696
3. Stevens CR, Williams RB, Farrell AJ, Blake DR: Hypoxia and inflammatory synovitis: observations and speculation. Ann Rheum Dis 1991, 50:124-132
4. Bjornheden T, Levin M, Evaldsson M, Wiklund O: Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999, 19:870-876
5. Lewis JS, Lee J, Underwood JCE, Harris AL, Lewis CE: Macrophage responses to hypoxia: implications for disease mechanisms. J Leukoc Biol 1999, 66:889-900
6. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000, 157:411-421
7. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, Lewis CE: Expression of HIF-1α by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002, 196:204-212
8. Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of HIF-1α by macrophages in the rheumatoid synovium: implications for targeting hypoxia-regulated gene therapy to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544
9. Crowther M, Brown NJ, Bishop ET, Lewis CE: Macrophage regulation of angiogenesis in wounds and malignant tumors: a response to common microenvironmental stress factors. J Leukoc Biol 2001, 70:478-490
10. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber H-P, Ferrara N, Johnson RS: HIF-1 is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657
11. Wenger RH: Mammalian oxygen sensing, signaling, and gene regulation. J Exp Biol 2000, 203:1253-1263
12. Semenza GL: HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000, 19:59-65
13. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D: Regulation of macrophage production of VEGF by hypoxia and TGF β-1. Ann Surg Oncol 1998, 5:271-278
14. Lewis JS, Landers RJ, Underwood JCE, Harris AL, Lewis CE: Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularized areas of breast carcinomas. J Pathol 2000, 192:150-158
15. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG, Sellke F, Carmeliet P, Simons M: PR39, a peptide regulator of angiogenesis. Nat Med 2000, 6:49-55
16. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56:4625-4629
17. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis CE, Harris AL, Kingsman S, Naylor SM: The macrophage: a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000, 7:255-262
18. Carta L, Pastorino S, Melillo G, Bosco MC, Massazza S, Varesio L: Engineering of macrophages to produce interferon-γ in response to hypoxia. J Immunol 2001, 166:5374-5380
19. Andreesen R, Hennemann B, Krause SW: Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998, 64:419-426
20. Grimshaw MJ, Balkwill FR: Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation: a potential mechanism. Eur J Immunol 2001, 31:480-489
21. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A: Regulation of GLUT-1 mRNA by hypoxia inducible factor-1: interaction between H-ras and hypoxia. J Biol Chem 2001, 276:9519-9525
22. Boast K, Binley K, Iqball S, Price T, Spearman H, Kingsman S, Kingsman A, Naylor S: Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999, 10:2197-2208
23. Crawford HC, Fingleton B, Gutsavson MD, Kurpios N, Wagenaar RA, Hassell JA, Matrisian LM: The PEA3 subfamily of ets transcription factors synergizes with β-catenin-LEF1 to activate matrilysin transcription in intestinal tumours. Mol Cell Biol 2001, 21:1370-1383
24. Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Aquisto F, Makuuchi M, Esumi H: Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2000, 276:2292-2298
25. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A: Regulation of GLUT-1 mRNA by hypoxia inducible factor-1: interaction between H-ras and hypoxia. J Biol Chem 2001, 276:9519-9525
26. Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, Stratford IJ: A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 2002, 2:282-290
27. Zhang JZ, Behrooz A, Ismail-Beigi F: Regulation of glucose transport by hypoxia. Am J Kidney Dis 1999, 34:189-202
28. Malinda KM, Goldstein AL, Kleinman HK: Thymosin β 4 stimulates directional migration of human umbilical vein endothelial cells. EMBO J 1997, 11:474-481
29. Huff T, Muller CS, Otto AM, Netzker R, Hannappel E: β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 2001, 33:205-220
30. Gondo H, Kudo J, White JW, Barr C, Selvanayagam P, Saunders GF: Differential expression of the human thymosin-β 4 gene in lymphocytes, macrophages, and granulocytes. J Immunol 1987, 139:3840-3848
31. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ: Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000, 60:883-887
32. Smith TA: FDG uptake, tumour characteristics, and response to therapy: a review. Nucl Med Commun 1998, 19:97-105
33. Ouiddir A, Planes C, Fernandes I, VanHesse A, Clerici C: Hypoxia up-regulates activity and expression of the glucose transporter GLUT-1 in alveolar epithelial cells. Am J Respir Cell Mol Biol 1999, 21:710-718
34. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003, 63:1138-1143
35. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: structures, evolution, and diversification. EMBO J 1998, 12:1075-1095
36. Murphy G, Cockett MI, Ward RV, Docherty AJ: Matrix metalloproteinase degradation of elastin, type IV collagen, and proteoglycan: a quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2, and punctuated metalloproteinase (PUMP). Biochem J 1991, 277:277-279
37. Sang OX: Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998, 8:171-178
38. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R: Matrix metalloproteinases and processing of pro-TNF-α. J Leukoc Biol 1995, 57:774-777
39. Wilson CL, Matrisian LM: Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem 1996, 28:123-136
40. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, Hultgren SJ, Matrisian LM, Parks WC: Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286:113-117
41. Rudek MA, Venitz J, Figg WD: Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 2002, 22:705-720
42. Busiek DF, Ross FP, McDonnell S, Murphy G, Matrisian LM, Welgus HG: The matrix metalloprotease, matrilysin (PUMP), is expressed in developing human mononuclear phagocytes. J Biol Chem 1992, 267:9087-9092
43. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996, 93:9748-9753
44. Shah PK: Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998, 3:199-206
45. Yamashita K, Azumano I, Mai M, Okada Y: Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas: implications for vessel invasion and metastasis. Int J Cancer 1998, 79:187-206
46. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001, 19:1118-1127
47. Shapiro SD: Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth. Thromb Haemost 1999, 82:846-849
48. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM: Matrilysin in early stage intestinal tumorigenesis. APMIS 1999, 107:102-110
49. Nishizuka I, Ichikawa Y, Ishikawa T, Kamiyama M, Hasegawa S, Momiyama N, Miyazaki K, Shimada H: Matrilysin stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo. Cancer Lett 2001, 173:175-182
50. Huo N, Ichikawa Y, Kamiyama M, Ishikawa T, Hamaguchi Y, Hasegawa S, Nagashima Y, Miyazaki K, Shimada H: MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett 2002, 177:95-100
51. Matrisian LM, Wright J, Newell K, Witty JP: Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 1994, 24:152-161
52. Mitsiades N, Yu W, Poulaki V, Tsokos M, Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001, 61:577-581
53. Sanna K, Rofstad EK: Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 1994, 58:258-262
54. Leek RD, Landers RJ, Harris AL, Lewis CE: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999, 79:991-995
55. Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P: Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001, 21:1834-1839
56. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D: Induction of interleukin 6 (IL-6) by hypoxia in vascular cells: central role of the binding site for nuclear factor-IL-6. J Biol Chem 1995, 270:11463-11471
57. Roesler WJ: The role of C/EBP in nutrient and hormonal regulation of gene expression. Ann Rev Nutr 2001, 21:141-165
58. Yan SF, Zou YS, Mendelsohn M, Gao Y, Naka Y, Du Yan S, Pinsky D, Stern D: Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. J Biol Chem 1997, 272:4287-4294
59. Ozaki I, Mizuta T, Zhao G, Yotsumoto H, Hara T, Kajihara S, Hisatomi A, Sakai T, Yamamoto K: Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res 2000, 60:6519-6525
60. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y: Hypoxia induces transcription factor Ets-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 2001, 289:39-43
61. Sun XH, Copeland NG, Jenkins NA, Baltimore D: Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol 1991, 11:5603-5611
62. Andrews-Barquin PJ, Hernandez MC, Israel MA: Id2 genes in nervous system development. Histol Histopathol 2000, 15:603-618
63. Kroog GS, Jensen RT, Battey JF: Mammalian bombesin receptors. Med Res Rev 1995, 15:389-417
64. Ohki-Hamazaki H: Neuromedin B. Prog Neurobiol 2000, 62:297-312